NEXVIAZYME (alglucosidase alfa) is a treatment for Pompe disease. Its instructions for use and pharmacological effects are important for patients and healthcare professionals. This article aims to provide detailed instructions for use of NEXVIAZYME for patients to refer to.

NEXVIAZYME Usage Guidelines

The correct use of NEXVIAZYME is important for the treatment of patients with Pompe disease. The following is a detailed introduction.

Dosage and Administration

NEXVIAZYME is administered by intravenous infusion. The recommended dose is adjusted according to the patient's weight. For patients weighing 30 kg and above, the dose is 20 mg/kg every two weeks; for patients weighing less than 30 kg, it is 40 mg/kg every two weeks. The initial infusion rate should be controlled at 1 mg/kg/hour, and then gradually increased to the recommended maximum rate based on the patient's tolerance.

Reconstitution and dilution

NEXVIAZYME is a lyophilized powder injection. It needs to be reconstituted with sterile water for injection and diluted to the appropriate concentration before use. Avoid vigorous stirring during reconstitution to reduce foaming. Use immediately after dilution, and discard unused dilution within the specified time.

Adverse reaction monitoring

During the use of NEXVIAZYME, patients should be closely monitored for adverse reactions, including allergic reactions, infusion-related reactions, etc. Once adverse reactions occur, appropriate measures should be taken immediately, such as slowing down the infusion rate, stopping the drug, etc.

Medication for special populations

For special populations such as pregnant women, lactating women, children and elderly patients, special caution should be exercised when using NEXVIAZYME. The dose should be adjusted according to the specific situation of the patient, and the medication reaction should be closely monitored.

Mastering the correct use of NEXVIAZYME is of great significance for the safe and effective treatment of Pompe disease in patients. Medical professionals should strictly follow the medication guidelines and adjust the treatment plan according to the patient's condition.

Basic pharmacological effects of NEXVIAZYME

Understanding the pharmacological effects of NEXVIAZYME will help to deeply understand its mechanism for the treatment of Pompe disease and provide a theoretical basis for clinical application.

Mechanism of Action

NEXVIAZYME is a recombinant human acid α-glucosidase that can replace the enzyme lacking in Pompe disease patients, thereby breaking down the accumulated glycogen in the body, improving cell function, and alleviating disease symptoms.

Indications and Efficacy

NEXVIAZYME is suitable for the treatment of patients with late-onset Pompe disease aged 1 year and above. Clinical trials have shown that the drug can significantly improve patients' respiratory function, exercise endurance, and quality of life.

Pharmacokinetic Properties

NEXVIAZYME has specific pharmacokinetic properties in the absorption, distribution, metabolism, and excretion of the body. Understanding these properties helps predict the behavior of the drug in the body and provides a basis for dose adjustment.

Drug Interactions

Currently, the interaction between NEXVIAZYME and other drugs is unclear. Therefore, when using NEXVIAZYME, the possibility of combined medication should be carefully considered and the patient's response should be closely monitored.

NEXVIAZYME plays a role in treating Pompe disease by supplementing the enzymes lacking in the patient's body. Understanding its pharmacological actions, indications, efficacy and pharmacokinetic properties is of great significance for guiding clinical applications.